Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Hepatocellular 20Nasopharyngeal Carcinoma 12Triple Negative Breast Neoplasms 11Esophageal Neoplasms 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Hodgkin Disease 5Recurrence 4Colorectal Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3NSCLC 3Advanced Gastric Cancer 3Respiratory Tract Diseases 2Rectal Neoplasms 2Osteosarcoma 2Neoplasms 2Nasopharyngeal Neoplasms 2Metastatic Gastric Adenocarcinoma 2Lymphoma, Extranodal NK-T-Cell 2Lung Diseases 2

Interventions

Gefitinib 9Pemetrexed 7Carboplatin 5Gemcitabine 4Cisplatin 4apatinib 3Docetaxel 3aflutinib 2Neoadjuvant Therapy 2Erlotinib Hydrochloride 2Bevacizumab 2tislelizumab 1pembrolizumab 1motesanib diphosphate 1lometrexol 1icotinib 1endostar protein 1camrelizumab 1Watchful Waiting 1Thymalfasin 1Radiomics 1Platinum Compounds 1Paclitaxel 1Lymph Node Excision 1Indium 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Folic Acid 1Exome 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma of Lung × camrelizumab × Clear all
NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Hunan Cancer Hospital

Phase 2 Unknown
63 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡